Skip to content
Sixfold Bioscience logo

Sixfold Bioscience

Sixfold Bioscience is a YC Winter 2018 (W18) company. Based in London, England, United Kingdom. Team of 27.

  • Gene Therapy
  • Nanomedicine
  • Drug Delivery

About Sixfold Bioscience

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Sixfold Bioscience builds patented drug delivery systems for RNA therapeutics, including siRNAs for gene silencing and mRNAs for gene expression. Its Mergo platform uses AI to engineer delivery vehicles, replacing conventional formulation approaches that struggle to get RNA into target cells reliably. Pharmaceutical and biotech developers working on RNA-based medicines are the intended customers.

Go-to-market

Sixfold Bioscience targets pharmaceutical and biotech companies developing RNA therapeutics, offering its Mergo platform as a delivery solution they can license or partner on rather than build in-house.

From the Y Combinator listing

How Sixfold Bioscience describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Delivering RNA therapies.

Sixfold is focused on the commercialisation of its patented drug delivery systems for RNA therapeutics such as siRNAs for gene silencing and mRNAs for gene expression.

Facts

Industry
Healthcare / Healthcare -> Drug Discovery and Delivery
Location
London, England, United Kingdom
Team size
27
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works